Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasms × Radiation Dose Hypofractionation × Clear all

Phase

Phase NA 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 6 Sarcoma 5 Prostatic Neoplasms 5 Carcinoma, Non-Small-Cell Lung 4 Lung Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 2 Liposarcoma, Myxoid 2 Carcinoma, Intraductal, Noninfiltrating 2 Advanced Refractory Solid Tumors 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Thymoma 1 Small Cell Lung Carcinoma 1 Small Cell Lung Cancer Limited Stage 1 Sarcoma, Synovial 1 Pancreatic Neoplasms 1 Neurofibrosarcoma 1 Neoplasms 1 Myosarcoma 1 Melanoma 1 Lymphatic Metastasis 1 Lymphangiosarcoma 1 Liposarcoma 1 Limited Stage Small Cell Lung Cancer 1 Leiomyosarcoma 1 Infiltrating Bladder Urothelial Carcinoma 1 Histiocytoma, Malignant Fibrous 1 Histiocytic Sarcoma 1 Head and Neck Neoplasms 1 Fibrosarcoma 1

Interventions

Bevacizumab 45 Gemcitabine 44 Cyclophosphamide 39 Carboplatin 37 Docetaxel 34 Fluorouracil 32 Cisplatin 32 Paclitaxel 31 pembrolizumab 28 Oxaliplatin 25 Radiotherapy 24 Irinotecan 23 Leucovorin 22 Capecitabine 22 Dexamethasone 21 Cetuximab 21 Nivolumab 19 Pemetrexed 18 Drug Therapy 18 Doxorubicin 18 Erlotinib Hydrochloride 17 Trastuzumab 15 Rituximab 15 Prednisone 15 durvalumab 14 atezolizumab 13 Sorafenib 13 fludarabine 12 Lapatinib 12 Everolimus 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02947113 2017-11-30

HYPOLAN

The Netherlands Cancer Institute

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡